TIDMAGL
RNS Number : 9645U
Angle PLC
30 October 2017
For immediate release 30 October 2017
ANGLE plc ("the Company")
Result of General Meeting
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that further to the announcement of
5 October 2017, the Resolutions put to Shareholders at the General
Meeting earlier today were duly passed. Completion of the
Acquisition, Placing and General Subscription are conditional on
admission of the EIS/VCT Placing Shares becoming effective at 8.00
a.m. on 31 October 2017 ("EIS/VCT Admission") and Admission of the
General Placing Shares and General Subscription Shares becoming
effective at 8.00 a.m. on 1 November 2017 ("General
Admission").
Completion of the Acquisition is conditional on General
Admission, with the Company having received approval of the
transaction by the Ontario Superior Court of Justice on 19 October
2017.
The Covington Subscription remains conditional upon, inter alia,
Completion, General Admission and Covington Admission at 8.00 a.m.
on 16 November 2017.
With effect from Admission of the Placing Shares and General
Subscription Shares, the Company will have 112,507,353 Ordinary
Shares in issue, with no shares held in treasury. Shareholders may
use this figure as the denominator by which they are required to
notify their interest in, or change to their interest in, the
Company under the Disclosure Guidance and Transparency Rules.
Following his subscription for 114,286 Ordinary Shares pursuant
to the General Subscription, Ian Griffiths, Finance Director of the
Company, will have a beneficial interest in 673,832 Ordinary Shares
representing approximately 0.60 per cent of the issued share
capital following General Admission.
Capitalised terms not otherwise defined in this announcement
shall have the same meaning ascribed to such terms in the
announcement entitled "Acquisition and Fundraising" released on 5
October 2017 unless the context requires otherwise.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Ian Griffiths
--- ------------------------------- --------------------------
2. Reason for the Notification
--- -----------------------------------------------------------
a) Position/status Finance Director
--- ------------------------------- --------------------------
b) Initial notification/Amendment Initial notification
--- ------------------------------- --------------------------
3. Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
--- -----------------------------------------------------------
a) Name ANGLE plc
--- ------------------------------- --------------------------
b) LEI 213800BY11K6W3NMS374
--- ------------------------------- --------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------
a) Description of Ordinary shares of 10p
the Financial each
instrument, type
of instrument
---
Identification AGL GB0034330679
code
--- ------------------------------- --------------------------
b) Nature of the Subscription for Ordinary
transaction Shares
--- ------------------------------- --------------------------
c) Price(s) and volume(s) Volume - 114,286
Price - 35p
--- ------------------------------- --------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
--- ------------------------------- --------------------------
e) Date of the transaction 30 October 2017
--- ------------------------------- --------------------------
f) Place of the transaction London Stock Exchange,
AIM Market (XLON)
--- ------------------------------- --------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMLLFFIITLIVID
(END) Dow Jones Newswires
October 30, 2017 06:31 ET (10:31 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
